drug_type
RELEVANT_DRUG
intervention_type
bispecific TCR/anti‑CD3 fusion protein (ImmTAC) biologic
drug_description
ImmTAC bispecific (IMC‑F106C): affinity‑enhanced PRAME‑specific TCR fused to anti‑CD3 scFv that binds PRAME peptide presented by HLA‑A*02:01 on tumor cells and recruits/activates T cells via CD3 to kill PRAME+ cells.
nci_thesaurus_concept_id
C199026
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
ImmTAC bispecific composed of an affinity‑enhanced PRAME‑specific TCR fused to an anti‑CD3 scFv; binds PRAME peptide presented by HLA‑A*02:01 on tumor cells and simultaneously engages CD3 on T cells, activating and redirecting polyclonal T cells to kill PRAME‑positive cells.
drug_name
Brenetafusp
nct_id_drug_ref
NCT06112314